Navigation Links
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
Date:3/25/2009

- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales -

- Company to Host Conference Call at 11:00 a.m. ET Today -

EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections without causing resistance, today announced that it has entered into an agreement with Galderma S.A. to develop and commercialize NovaBay's novel proprietary Aganocide(R) compounds. The exclusive agreement is worldwide in scope, with the exception of certain Asian markets, and covers all major dermatological conditions, excluding onychomycosis (nail fungus) and orphan drug indications.

Under the terms of the agreement, NovaBay expects to receive from Galderma up to $50 million upon achievement of certain development and regulatory milestones related to the acne and impetigo indications and future royalties on net sales of products. The agreement also envisages further cooperation for additional dermatological products and indications. Under the agreement, NovaBay will also receive escalating double-digit royalties on net sales of products.

Galderma will be responsible for the development costs of the acne and other indications, except in Japan, and for the ongoing development program for impetigo, upon the achievement of a specified milestone. Galderma will also reimburse NovaBay for the use of its personnel in support of the collaboration. NovaBay retains the right to co-market products resulting from the agreement in Japan. In addition, NovaBay has retained all rights in other Asian markets outside Japan, and has exclusive rights to promote the products developed under the agreement in the hos
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
2. Galderma Completes Acquisition of CollaGenex
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
6. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
7. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
8. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
9. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
10. Neogen Acquires Kane Enterprises
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... Vical Incorporated (Nasdaq:,VICL) today reported financial results for the quarter ... were $0.8 million, compared,with revenues of $0.4 million for the ... of 2008 was $9.8 million or $0.24 per share, compared,with ... of 2007., Revenues for the first nine months of ...
... - New business awards of $212 million, up 21% from third ... 2008, up 16% ... from Dec. 31, 2007, CINCINNATI, Nov. 4 Kendle ... income of $11.0 million or $0.73 per diluted share for its third,quarter ended ...
... Nov. 4 Danaher Corporation (NYSE:,DHR) announced that ... Comas will be presenting at the Robert W. ... 12, 2008 at 1:55 p.m. CST.,The audio will ... Danaher Corporation is a leading manufacturer of Professional,Instrumentation, ...
Cached Biology Technology:Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 2Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 3Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 4Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 5Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 6Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 7Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations 8
(Date:8/21/2014)... from North Carolina State University have developed a novel ... model has applications for creating new materials as well ... "Our new technique allows us to model much larger ... much more quickly," says Nan Li, lead author of ... in NC State,s Department of Materials Science and Engineering. ...
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor of ... named a fellow in the International Society for the Study ... one of four members two from the U.S., one ... in 2014. Fellows are elected every three years, and 36 ... from more than 20 countries, the ISSOL includes researchers from ...
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... has been intimately entwined since Lon Foucault discovered the speed ... more slowly in water than in air. This physical harmony ... and drive light to where it can be the most ... optofluidics, the study of microfluidicsthe microscopic delivery of fluids through ...
... induced pluripotent stem cells were first derived in 2007, scientists ... cells, which are sourced in early-stage embryos. Both cell ... the body, but their origins in embryonic and adult ... both cell types have great potential in basic biological research ...
... Homeowners and taxpayers are picking up most of the ... inadvertently imported along with packing materials, live plants, and other ... economists, whose research findings are reported in the journal ... that non-native, wood-boring insects such as the emerald ash borer ...
Cached Biology News:A guiding light for new directions in energy production 2A guiding light for new directions in energy production 3Study reveals critical similarity between two types of do-it-all stem cells 2Study reveals critical similarity between two types of do-it-all stem cells 3Invasive forest insects cost homeowners, taxpayers billions 2
... nucleotide structure called a ?cap? is ... naturally-occurring eukaryotic mRNAs and many viral ... a portion of the GTP present ... results in the synthesis of transcripts ...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
... structure called a ?cap? is present ... eukaryotic mRNAs and many viral RNAs. ... portion of the GTP present in ... in the synthesis of transcripts with ...
... Orbital Shakers have the durability ... stacked 3-high, and the uniformity ... "soft shake" applications. Heavily ... systems, our stackers are designed ...
Biology Products: